Patent Grant
12004803
The present technology relates to relates generally to devices, systems, and methods for removing obstructions from body lumens. Some embodiments of the present technology relate to devices and methods for delivering electrical current within a medical treatment system.
Many medical procedures use medical device(s) to remove an obstruction (such as clot material) from a body lumen, vessel, or other organ. An inherent risk in such procedures is that mobilizing or otherwise disturbing the obstruction can potentially create further harm if the obstruction or a fragment thereof dislodges from the retrieval device. If all or a portion of the obstruction breaks free from the device and flows downstream, it is highly likely that the free material will become trapped in smaller and more tortuous anatomy. In many cases, the physician will no longer be able to use the same retrieval device to again remove the obstruction because the device may be too large and/or immobile to move the device to the site of the new obstruction.
Procedures for treating ischemic stroke by restoring flow within the cerebral vasculature are subject to the above concerns. The brain relies on its arteries and veins to supply oxygenated blood from the heart and lungs and to remove carbon dioxide and cellular waste from brain tissue. Blockages that interfere with this blood supply eventually cause the brain tissue to stop functioning. If the disruption in blood occurs for a sufficient amount of time, the continued lack of nutrients and oxygen causes irreversible cell death. Accordingly, it is desirable to provide immediate medical treatment of an ischemic stroke.
To access the cerebral vasculature, a physician typically advances a catheter from a remote part of the body (typically a leg) through the abdominal vasculature and into the cerebral region of the vasculature. Once within the cerebral vasculature, the physician deploys a device for retrieval of the obstruction causing the blockage. Concerns about dislodged obstructions or the migration of dislodged fragments increases the duration of the procedure at a time when restoration of blood flow is paramount. Furthermore, a physician might be unaware of one or more fragments that dislodge from the initial obstruction and cause blockage of smaller more distal vessels.
Many physicians currently perform thrombectomies (i.e. clot removal) with stents to resolve ischemic stroke. Typically, the physician deploys a stent into the clot in an attempt to push the clot to the side of the vessel and re-establish blood flow. Tissue plasminogen activator (“tPA”) is often injected into the bloodstream through an intravenous line to break down a clot. However, it takes time for the tPA to reach the clot because the tPA must travel through the vasculature and only begins to break up the clot once it reaches the clot material. tPA is also often administered to supplement the effectiveness of the stent. Yet, if attempts at clot dissolution are ineffective or incomplete, the physician can attempt to remove the stent while it is expanded against or enmeshed within the clot. In doing so, the physician must effectively drag the clot through the vasculature, in a proximal direction, into a guide catheter located within vessels in the patient's neck (typically the carotid artery). While this procedure has been shown to be effective in the clinic and easy for the physician to perform, there remain some distinct disadvantages to using this approach.
For example, one disadvantage is that the stent may not sufficiently retain the clot as it pulls the clot to the catheter. In such a case, some or all of the clot might remain in the vasculature. Another risk is that, as the stent mobilizes the clot from the original blockage site, the clot might not adhere to the stent as the stent is withdrawn toward the catheter. This is a particular risk when passing through bifurcations and tortuous anatomy. Furthermore, blood flow can carry the clot (or fragments of the clot) into a branching vessel at a bifurcation. If the clot is successfully brought to the end of the guide catheter in the carotid artery, yet another risk is that the clot may be “stripped” or “sheared” from the stent as the stent enters the guide catheter.
In view of the above, there remains a need for improved devices and methods that can remove occlusions from body lumens and/or vessels.
Mechanical thrombectomy (e.g., clot-grabbing and removal) has been effectively used for treatment of ischemic stroke. Although most clots can be retrieved in a single pass attempt, there are instances in which multiple attempts are needed to fully retrieve the clot and restore blood flow through the vessel. Additionally, there exist complications due to detachment of the clot from the interventional element during the retrieval process as the interventional element and clot traverse through tortuous intracranial vascular anatomy. For example, the detached clot or clot fragments can obstruct other arteries leading to secondary strokes. The failure modes that contribute to clot release during retrieval are: (a) boundary conditions at bifurcations; (b) changes in vessel diameter; and (c) vessel tortuosity, amongst others.
Certain blood components, such as platelets and coagulation proteins, display negative electrical charges. The treatment systems of the present technology provide an interventional element and a current generator configured to positively charge the interventional element during one or more stages of a thrombectomy procedure. For example, the current generator may apply a constant or pulsatile direct current (DC) to the interventional element. The positively charged interventional element attracts negatively charged blood components, thereby improving attachment of the thrombus to the interventional element and reducing the number of device passes or attempts necessary to fully retrieve the clot. In some aspects of the present technology, the treatment system includes an elongate core assembly (e.g., a cable) extending between the current generator and the interventional element. A delivery electrode may be integrated into the core assembly and/or interventional element, and the treatment system further includes a negative electrode that may be disposed at a number of different locations. For example, the negative electrode can be a wire coupled to or integrated within the core assembly. Additionally or alternatively, a negative electrode can take the form of a needle, a grounding pad, a conductive element carried by a one or more catheters of the treatment system, a separate guide wire, and/or any other suitable conductive element configured to complete an electrical circuit with the delivery electrode and the extracorporeally positioned current generator. When the interventional element is placed in the presence of blood (or any other electrolytic medium) and voltage is applied at the terminals of the current generator, current flows along the core assembly to the interventional element, through the blood, and to the return electrode, thereby positively charging at least a portion of the interventional element and adhering clot material thereto.
One approach to delivering current to an interventional element is to conduct current along a core member coupled to a proximal end of the interventional element. However, the inventors have discovered that this approach can lead to disadvantageous concentration of electrical charge along a proximal portion of the interventional element, with insufficient charge density in more distal portions of the interventional element (e.g., along some or all of the working length of the interventional element). This is particularly true of an interventional element having a proximal portion that tapers to a connection point with the core member. This concentration of current in the proximal portion can reduce the efficacy of electrostatic enhancement of clot adhesion, as the mechanical clot engagement occurs primarily at a location distal to the region at which the charge density is greatest. Additionally, when used in an aqueous chloride environment, such as the blood, hydrogen and chlorine gas bubbles can form along the surface of the interventional element in areas with high surface charge density (e.g., along a proximal portion of the interventional element). To reduce risk to the patient and ensure the treatment system functions properly, it may be beneficial to ensure that current flows through the entire interventional element, particularly ensuring sufficient current density in distal portions of the interventional element. When the entire interventional element exhibits a positive electrical charge, all portions of the interventional element can attract negatively charged blood components, thereby improving attachment of the thrombus to the interventional element. If portions of the interventional element are not positively charged (e.g., the distal portion is electrically neutral or exhibits insufficient charge density), those portions of the interventional element may not adequately attract negatively charged blood components, which can prevent improved attachment of the thrombus to the interventional element.
Embodiments of the present technology address these and other problems by providing a core assembly that positions negative electrode(s) relative to the interventional element at locations that facilitate current distribution across the interventional element. For example, to encourage current to flow through all portions of the interventional element, the negative electrode can be positioned at or distal to the interventional element in a manner that encourages current to flow through all portions of the interventional element. In some embodiments, the core assembly can take the form of an elongated conductor such as a wire, with an insulation material surrounding the wire along its length. The insulation material can include gaps or apertures along a distal region of the wire that define negative electrode(s). These uninsulated sections can be located at specific locations that encourage current to flow through the entire interventional element. For example, one or more negative electrodes can be located proximate the distal end of the interventional element, which encourages current to flow to the distal end of the interventional element. By positioning one or more electrode portions at advantageous locations, the interventional element can reliably maintain a positive charge during treatment.
Additional features and advantages of the present technology are described below, and in part will be apparent from the description, or may be learned by practice of the present technology. The advantages of the present technology will be realized and attained by the structure particularly pointed out in the written description and claims hereof as well as the appended drawings. The subject technology is illustrated, for example, according to various aspects described below. Various examples of aspects of the subject technology are described as numbered clauses (1, 2, 3, etc.) for convenience. These are provided as examples and do not limit the subject technology.
Many aspects of the present disclosure can be better understood with reference to the following drawings. The components in the drawings are not necessarily to scale. Instead, emphasis is placed on clearly illustrating the principles of the present disclosure.
The present technology provides devices, systems, and methods for removing clot material from a blood vessel lumen. Although many of the embodiments are described below with respect to devices, systems, and methods for treating a cerebral or intracranial embolism, other applications and other embodiments, in addition to those described herein, are within the scope of the technology. For example, the treatment systems and methods of the present technology may be used to remove emboli from body lumens other than blood vessels (e.g., the digestive tract, etc.) and/or may be used to remove emboli from blood vessels outside of the brain (e.g., pulmonary, abdominal, cervical, or thoracic blood vessels, or peripheral blood vessels including those within the legs or arms, etc.). In addition, the treatment systems and methods of the present technology may be used to remove luminal obstructions other than clot material (e.g., plaque, resected tissue, foreign material, etc.). In some embodiments, aspects of the present technology can be applied to medical devices and systems that are not configured for removal of material from vessel lumens, for example systems and devices for ablation, neuromodulation, or any other suitable medical procedure.
The core assembly 105 is configured to be slidably disposed within the lumen of the third catheter 114. In the illustrated embodiment, the core assembly 105 can take the form of an electrical cable or other such assembly that includes a first electrical conductor 116 and a second electrical conductor 118. As discussed in more detail below, in some instances the first conductor 116 can take the form of an elongated tube (e.g., a hypotube) made of or including an electrically conductive material, and the second conductor 118 can take the form of an elongated wire or rod that is made of or includes an electrically conductive material. In some embodiments, the second conductor 118 is configured to be disposed within a lumen of the first conductor 116. In some embodiments, the first conductor 116 and second conductor 118 are coaxial. In various embodiments, the first conductor 116 and second conductor 118 are non-slidably coupled together. The first conductor 116 and second conductor 118 can be sized and configured to be advanced through a corporeal lumen to the treatment site. For example, the first conductor 116 and second conductor 118 can be sized to be positioned proximate a thrombus within a lumen of a blood vessel, such as within a patient's neurovasculature. The first conductor 116 and/or the second conductor 118 can be electrically insulated along at least a portion of their respective lengths. In some embodiments, the first catheter 110 can be coupled to (or incorporate) the handle 108, which provides proximal access to the first conductor 116 and second conductor 118.
The current generator 102 may be coupled to the core assembly 105 to deliver electrical current to the interventional element 106 and thereby provide an electrically charged environment at the distal portion 104b of the treatment device 104. Further, the current generator 102 may be coupled to the core assembly 105 to return electrical current from the electrically charged environment to the current generator 102. In various embodiments, the current generator 102 can be electrically coupled to the first conductor 116, the second conductor 118, or both.
In some embodiments, the treatment system 100 includes a suction source 120 (e.g., a syringe, a pump, etc.) configured to be fluidically coupled (e.g., via a connector 122) to a proximal portion of one or more of the first catheter 110, the second catheter 112, and/or the third catheter 114 to apply negative pressure therethrough. In some embodiments, the treatment system 100 includes a fluid source 124 (e.g., a fluid reservoir, a syringe, pump, etc.) configured to be fluidically coupled (e.g., via the connector 122) to a proximal portion of one or more of the first catheter 110, the second catheter 112, and/or the third catheter 114 to supply fluid (e.g., saline, contrast agents, a drug such as a thrombolytic agent, etc.) to the treatment site.
According to some embodiments, the catheters 110, 112, and 114 can each be formed as a generally tubular member extending along and about a central axis. According to some embodiments, the third catheter 114 is generally constructed to track over a conventional guidewire in the cervical anatomy and into the cerebral vessels associated with the brain and may also be chosen according to several standard designs that are generally available. Accordingly, the third catheter 114 can have a length that is at least 125 cm long, and more particularly may be between about 125 cm and about 175 cm long. Other designs and dimensions are contemplated.
The second catheter 112 can be sized and configured to slidably receive the third catheter 114 therethrough. As noted above, the second catheter 112 can be coupled at a proximal portion to a suction source 120 (
According to some embodiments, the bodies of the catheters 110, 112, and 114 can be made from various thermoplastics, e.g., polytetrafluoroethylene (PTFE or TEFLON®), fluorinated ethylene propylene (FEP), high-density polyethylene (HDPE), polyether ether ketone (PEEK), etc., which can optionally be lined on the inner surface of the catheters or an adjacent surface with a hydrophilic material such as polyvinylpyrrolidone (PVP) or some other plastic coating. Additionally, either surface can be coated with various combinations of different materials, depending upon the desired results.
In some embodiments, the current generator 102 may be coupled to a proximal portion of the first conductor 116, and/or a proximal portion of the third catheter 114, the second catheter 112, and/or first catheter 110 to provide an electric current to the interventional element 106. For example, as shown in
The system can include multiple (e.g., two or more), distinct conductive paths or channels for passing electrical current along the system. The interventional element 106 can serve as one electrode (e.g., a positive electrode) in electrical communication with a conductive path via the first conductor 116. Another of the conductive paths of the system can be in electrical communication with another electrode (e.g., a negative electrode). For example, the second conductor 118 can serve as the second conductive path, with one or more uninsulated portions of the second conductor 118 forming the negative electrode(s).
As shown in
In certain embodiments, the polarities of the current generator 102 can be switched, so that the negative electrical connector is electrically coupled to the first conductor 116 and the positive electrical connector is electrically coupled to the second conductor 118. This can be advantageous when, for example, attempting to attract predominantly positively charged material to the interventional element 106, or when attempting to break up a clot rather than grasp it with an interventional element 106. In some embodiments alternating current (AC) signals may be used rather than DC. In certain instances, AC signals may advantageously help break apart a thrombus or other material.
In various embodiments, the interventional element 106 can take any number of forms, for example a removal device, a thrombectomy device, or other suitable medical device. For example, in some embodiments the interventional element 106 may be a stent and/or stent retriever, such as Medtronic's Solitaire™ Revascularization Device, Stryker Neurovascular's Trevo® ProVue™ Stentriever, or other suitable devices. In some embodiments, the interventional element 106 may be a coiled wire, a weave, and/or a braid formed of a plurality of braided filaments. Examples of suitable interventional elements 106 include any of those disclosed in U.S. Pat. No. 7,300,458, filed Nov. 5, 2007, U.S. Pat. No. 8,940,003, filed Nov. 22, 2010, U.S. Pat. No. 9,039,749, filed Oct. 1, 2010, and U.S. Pat. No. 8,066,757, filed Dec. 28, 2010, each of which is incorporated by reference herein in its entirety.
The interventional element 106 can have a low-profile, constrained or compressed configuration for intravascular delivery to the treatment site within the third catheter 114, and an expanded configuration for securing and/or engaging clot material and/or for restoring blood flow at the treatment site. The interventional element 106 has a proximal portion including an attachment portion 106a that may be coupled to the first conductor 116 and a distal portion comprising an open cell framework or body 106b. In some embodiments, the body 106b of the interventional element 106 can be generally tubular (e.g., cylindrical), and the proximal portion of the interventional element 106 can taper proximally to the attachment portion 106a. In various embodiments, the interventional element 106 can define a lumen that is located radially inward from the body 106b.
The interventional element 106 can be a metallic and/or electrically conductive thrombectomy device. For example, the interventional element can include or be made of stainless steel, nitinol, cobalt-chromium, platinum, tantalum, alloys thereof, or any other suitable material. In some embodiments, the interventional element 106 is a mesh structure (e.g., a braid, a stent, etc.) formed of a superelastic material (e.g., Nitinol) or other resilient or self-expanding material configured to self-expand when released from the third catheter 114. The mesh structure may include a plurality of struts and open spaces between the struts. In some embodiments, the struts and spaces may be situated along the longitudinal direction of the interventional element 106, the radial direction, or both.
In some embodiments, the first conductor 116 can be a structural element configured to push and pull a device such as the interventional element 106 along the bodily lumen. The first conductor 116 can be any suitable elongate member configured to advance the interventional element 106 to a treatment site within a blood vessel. For example, the first conductor 116 can be or include a wire, tube (e.g., a hypotube), coil, or any combination thereof. According to some embodiments, the first conductor 116 comprises an elongate tubular member defining a lumen therethrough. In some embodiments, the first conductor 116 can comprise a distally located aperture configured to receive the attachment portion of the interventional element. In some embodiments, the first conductor 116 comprises a distally located joining element comprising the aperture configured to receive the attachment portion. The first conductor 116 can have a length sufficient to extend from a location outside the patient's body through the vasculature to a treatment site within the patient's body. The first conductor 116 can be a monolithic structure or formed of multiple joined segments. In some embodiments, the first conductor 116 can comprise a laser-cut hypotube having a spiral cut pattern (or other pattern of cut voids) formed in its sidewall along at least a portion of its length. The first conductor 116 can be metallic and/or otherwise electrically conductive to deliver current from the current generator 102 to the interventional element 106. For example, the first conductor 116 can comprise or consist of nickel titanium alloy, stainless steel, or other metals or alloys. In embodiments that comprise multiple joined segments, the segments may be of the same or different materials. For example, some or all of the first conductor 116 can be formed of stainless steel, or other suitable materials known to those skilled in the art. Nickel titanium alloy may be preferable for kink resistance and reduction of imaging artifacts.
In some embodiments, the second conductor 118 can be a structural element configured to secure or retain a position of the interventional element 106 relative to the first conductor 116. Additionally, or alternatively, the second conductor 118 can be configured to be a negative electrode. The second conductor 118 can be any suitable elongate member configured to extend through a lumen of the first conductor 116. For example, the second conductor 118 can be or include a wire, tube (e.g., a hypotube), coil, or any combination thereof. The second conductor 118 can have a length sufficient to extend from a location outside the patient's body through the vasculature to a treatment site within the patient's body. The second conductor 118 can be a monolithic structure or formed of multiple joined segments. The second conductor 118 can be metallic or electrically conductive to deliver current from the surrounding media (e.g., blood, tissue, thrombus, etc.) to the current generator 102. For example, the second conductor 118 can comprise or consist of nickel titanium alloy, stainless steel, or other metals or alloys. In embodiments that comprise multiple joined segments, the segments may be of the same or different materials. For example, some or all of the second conductor 118 can be formed of stainless steel, or other suitable materials known to those skilled in the art. Nickel titanium alloy may be preferable for kink resistance and reduction of imaging artifacts. The second conductor 118 can be electrically insulated along some or all of its length. In some embodiments, the second conductor 118 comprises an insulated wire or guide wire having one or more exposed, electrically conductive portions. For example, a distal end portion of the second conductor 118 can be exposed to conduct current from surrounding media (e.g., blood, tissue, thrombus, etc.) at a treatment site.
In some embodiments, the treatment device 104 can comprise one or more electrically insulating materials. For example, an insulating material can be disposed on one or more portions of the second conductor 118 to electrically isolate the second conductor 118 from the first conductor 116, the connection 126, and/or the interventional element 106. Additionally or alternatively, an insulating material can be disposed within a lumen of the first conductor 116 to electrically isolate the first conductor 116 from the second conductor 118 and/or the attachment portion of the interventional element 106. In some embodiments, an insulating material is disposed over an outer surface of the first conductor 116 along at least a portion of a length of the first conductor 116 to direct current through the first conductor 116 and prevent current loss from the first conductor 116 to the surrounding environment. As shown in
As shown in
In some embodiments, the connection 126 can comprise a bonding agent in addition or alternative to the joining element 128 and/or second conductor 118. The bonding agent can comprise adhesive, solder, welding flux, brazing filler, etc., disposed within the joining element 128, and/or adjacent to it, just proximal of and/or just distal of the joining element 128. In some embodiments, the bonding agent can bond to the connection 126 without applying heat. For example, the bonding agent can comprise a UV-curable adhesive. In embodiments that comprise a polymer coating of the wire or polymer tubing, use of a bonding agent that avoids application of heat that would damage the polymer may be preferred.
In some embodiments, the connection 126 can comprise a locking element. The locking element can be coupled with the joining element 128 and can be configured to inhibit motion of the attachment portion 106a. Examples of suitable locking elements can include any of the disclosed locking elements in U.S. Provisional Application No. 63/199,352 filed Dec. 21, 2020, which is hereby incorporated by reference in its entirety.
The second conductor 118 can include an insulative material 142 that surrounds the second conductor 118 and which has several openings formed within the insulative material 142. These openings can define electrode portions 140. The insulative material 142 can be the same, or similar to, the insulative material 127. Accordingly, the portions of the second conductor 118 that are surrounded by the insulative material 142 can be electrically isolated from other components, while the openings formed within the insulative material 142 can provide electrical access to the second conductor 118 at the openings. In some embodiments, the electrode portions 140 include a coating or other conductive element that is applied over the surface of the second conductor 118.
In various embodiments, the insulative material 142 can define the electrode portions 140. For example, as illustrated in
As illustrated in
As previously discussed, the insulating material 142 can define one or more electrode portions 140 of the second conductor 118. The electrode portions 140 can include one or more uninsulated portions of the second conductor 118 that allow for the second conductor 118 to electrically couple to other components via, e.g., surrounding media such as thrombus, blood, saline, tissue, etc. For example, as illustrated in
In various embodiments, the electrode portions 140 can include one or more openings 144 formed into the insulating material 142. For example, as illustrated in
In various embodiments, the electrode portions 140 can include one or more annular openings 146 formed into the insulating material 142. For example, as illustrated in
In various embodiments, the electrode portions 140 can include one or more spiral or helical openings 148 formed into the insulating material 142. For example, as illustrated in
In some embodiments, the electrode portions 140 can include a combination of openings formed in the insulating material 142. For example, in some embodiments, the electrode portions 140 can include one or more openings 144, one or more annular openings 146, and/or one or more spiral openings 148. In some embodiments, the electrode portion 140 can take the form of an uninsulated distal terminus 118b of the second conductor 118; such an electrode portion can be employed instead of or in addition to other electrode portion(s) 140 located along the length of the second conductor 118 proximal of the distal terminus 118b.
In some embodiments, some or all of the electrode portions 140 can include the same material as a part of the interventional element 106. For example, the uninsulated material of the second conductor 118 within the electrode portion 140 can be the same material as the interventional element 106. In some embodiments, the interventional element 106 is coated, plated or surface-treated with an outer layer of electrically conductive material, which can be the same material as the uninsulated portions of the second conductor 118.
In some embodiments, components of the treatment device 104 can electrically couple to the second conductor 118 through the electrode portions 140 (e.g. via surrounding media). Because the second conductor 118 is not electrically isolated completely at the electrode portions 140, the second conductor 118 can electrically couple to other components at the electrode portions 140. For example, in some embodiments, the interventional element 106 can couple to the second conductor 118 through the electrode portions 140. In various embodiments, the electrode portions 140 can be used to complete a circuit between the first conductor 116 and second conductor 118. For example, the current generator 102 can couple to the core assembly 105 at the proximal portion 104a of the treatment device 104 and send a current through the first conductor 116. This current can flow through the first conductor 116 to the interventional element 106. At the interventional element 106, the current can flow through the patient's surrounding media (e.g., blood, tissue, saline, thrombus, etc.) to the electrode portions 140 of the second conductor 118, where the current can then flow through the second conductor 118 and return to the current generator 102.
In various embodiments, the electrode portions 140 can be configured to prevent the circuit between the first conductor 116 and second conductor 118 from shorting. For example, by positioning the electrode portions 140 distally from the attachment portion 106a of the interventional element 106, the electrode portions 140 can prevent the circuit from shorting at proximate the attachment portion 106a. Additionally, in some embodiments, positioning the uninsulated portions of the second conductor 118 so that the uninsulated portions are proximate or radially adjacent to the spaces or cell openings 107 defined by the body 106b (e.g. by the struts thereof) can also prevent the circuit from shorting. In some embodiments, the electrode portions 140 can be configured to allow for the interventional element 106 to maintain a desirable electrical charge distribution. For example, positioning the electrode portions 140 proximate the distal terminus 118b of the second conductor 118 encourages the more current to flow through the distal portions of the interventional element 106 to reach the electrode portions 140, which in turn allows for the interventional element 106 to maintain a favorable electrical charge distribution (e.g., with sufficiently high charge density at the distal region of the interventional element, along the working length of the interventional element, or other suitable charge distribution). In some embodiments, spacing the openings (e.g. openings 144, annular openings 146, and/or spiral openings 148) of the electrode portions apart along the length of second conductor 118 can also allow for the interventional element 106 to maintain an electrical charge.
An example method of delivering a current to the treatment device 104 will now be described. First, the treatment device 104 is positioned within a patient at the treatment site. Once the treatment device 104 is properly positioned, the user can expand the interventional element 106 so that the interventional element 106 engages with the thrombus. After the interventional element 106 engages with the thrombus, the user can couple the core assembly 105 to the current generator 102. In some embodiments, the core assembly 105 is previously coupled to the current generator 102. The user can interact with current generator to initiate the supply of an electrical signal to the first conductor 116. The electrical signal can travel toward the treatment site through the first conductor 116 and to the interventional element 106. The electrical signal can return to the current generator 102 by flowing from the interventional element, through the surrounding media (e.g., blood, tissue, thrombus, etc.) to the electrode portions 140 of the second conductor 118 and through the second conductor 118 to the current generator 102. In some embodiments, the electrical signal is an electrical current of between about 0-5 mA. The electrical signal can be unipolar (e.g., DC) or bipolar (e.g., AC). In various embodiments, the current or voltage level of the electrical signal can be constant, periodic, irregular, or any combination thereof. In some embodiments, the electrical signal is supplied for a duration of time between about 30 seconds to about 10 minutes. In some embodiments, the electrical signal is supplied for a duration of time of two minutes or less. After the electrical signal is delivered to the treatment device 104 for the proper duration, the user can interact with current generator to stop the supply of the electrical signal. The user can then proximally retract the treatment device 104, including the thrombus, into a surrounding catheter, and then remove the entire assembly from the patient.
The descriptions of embodiments of the technology are not intended to be exhaustive or to limit the technology to the precise form disclosed above. Where the context permits, singular or plural terms may also include the plural or singular term, respectively. Although specific embodiments of, and examples for, the technology are described above for illustrative purposes, various equivalent modifications are possible within the scope of the technology, as those skilled in the relevant art will recognize. For example, while steps are presented in a given order, alternative embodiments may perform steps in a different order. The various embodiments described herein may also be combined to provide further embodiments.
Moreover, unless the word “or” is expressly limited to mean only a single item exclusive from the other items in reference to a list of two or more items, then the use of “or” in such a list is to be interpreted as including (a) any single item in the list, (b) all of the items in the list, or (c) any combination of the items in the list. Additionally, the term “comprising” is used throughout to mean including at least the recited feature(s) such that any greater number of the same feature and/or additional types of other features are not precluded. It will also be appreciated that specific embodiments have been described herein for purposes of illustration, but that various modifications may be made without deviating from the technology. Further, while advantages associated with certain embodiments of the technology have been described in the context of those embodiments, other embodiments may also exhibit such advantages, and not all embodiments need necessarily exhibit such advantages to fall within the scope of the technology. Accordingly, the disclosure and associated technology can encompass other embodiments not expressly shown or described herein.
| Number | Name | Date | Kind |
|---|---|---|---|
| 5549626 | Miller et al. | Aug 1996 | A |
| 5972019 | Engelson et al. | Oct 1999 | A |
| 6022336 | Zadno-Azizi et al. | Feb 2000 | A |
| 6059779 | Mills | May 2000 | A |
| 6315794 | Richter | Nov 2001 | B1 |
| 6540733 | Constantz et al. | Apr 2003 | B2 |
| 6663650 | Sepetka et al. | Dec 2003 | B2 |
| 7094249 | Broome et al. | Aug 2006 | B1 |
| 7520966 | Diaz et al. | Apr 2009 | B2 |
| 7556624 | Laufer et al. | Jul 2009 | B2 |
| 8038674 | Schmaltz et al. | Oct 2011 | B2 |
| 8382821 | Richter | Feb 2013 | B2 |
| 8603014 | Alleman et al. | Dec 2013 | B2 |
| 8837800 | Bammer et al. | Sep 2014 | B1 |
| 8888788 | Adams et al. | Nov 2014 | B2 |
| 9011431 | Long et al. | Apr 2015 | B2 |
| 9039753 | Thramann | May 2015 | B2 |
| 9119656 | Bose et al. | Sep 2015 | B2 |
| 9126018 | Garrison | Sep 2015 | B1 |
| 9179971 | Kirschenman | Nov 2015 | B2 |
| 9211132 | Bowman | Dec 2015 | B2 |
| 9241699 | Kume et al. | Jan 2016 | B1 |
| 9265512 | Garrison et al. | Feb 2016 | B2 |
| 9308007 | Cully et al. | Apr 2016 | B2 |
| 9399118 | Kume et al. | Jul 2016 | B2 |
| 9445828 | Turjman et al. | Sep 2016 | B2 |
| 9445829 | Brady et al. | Sep 2016 | B2 |
| 9492637 | Garrison et al. | Nov 2016 | B2 |
| 9539022 | Bowman | Jan 2017 | B2 |
| 9561345 | Garrison et al. | Feb 2017 | B2 |
| 9579119 | Cully et al. | Feb 2017 | B2 |
| 9585741 | Ma | Mar 2017 | B2 |
| 9642635 | Vale et al. | May 2017 | B2 |
| 9655633 | Leynov et al. | May 2017 | B2 |
| 9681882 | Wilson et al. | Jun 2017 | B2 |
| 9713730 | Mathur et al. | Jul 2017 | B2 |
| 9737318 | Monstadt et al. | Aug 2017 | B2 |
| 9770251 | Bowman et al. | Sep 2017 | B2 |
| 9795400 | Davidson | Oct 2017 | B2 |
| 9801643 | Hansen et al. | Oct 2017 | B2 |
| 9808271 | Ulm | Nov 2017 | B2 |
| 9827084 | Bonnette et al. | Nov 2017 | B2 |
| 9861783 | Garrison et al. | Jan 2018 | B2 |
| 9993257 | Losordo et al. | Jun 2018 | B2 |
| 10028782 | Orion | Jul 2018 | B2 |
| 10029008 | Creighton | Jul 2018 | B2 |
| 10039906 | Kume et al. | Aug 2018 | B2 |
| 10092241 | Toth et al. | Oct 2018 | B2 |
| 10251569 | Burkett | Apr 2019 | B2 |
| 10709463 | Girdhar | Jul 2020 | B2 |
| 20010001314 | Davison et al. | May 2001 | A1 |
| 20020059938 | Fogarty et al. | May 2002 | A1 |
| 20020133111 | Shadduck et al. | Sep 2002 | A1 |
| 20040219660 | Dev et al. | Nov 2004 | A1 |
| 20060089638 | Carmel | Apr 2006 | A1 |
| 20080042662 | Abraham | Feb 2008 | A1 |
| 20080045881 | Teitelbaum et al. | Feb 2008 | A1 |
| 20080262489 | Steinke et al. | Oct 2008 | A1 |
| 20080294181 | Wensel et al. | Nov 2008 | A1 |
| 20090054918 | Henson | Feb 2009 | A1 |
| 20090069828 | Martin et al. | Mar 2009 | A1 |
| 20100004623 | Hamilton et al. | Jan 2010 | A1 |
| 20100010533 | Burke et al. | Jan 2010 | A1 |
| 20100042136 | Berrada et al. | Feb 2010 | A1 |
| 20100256627 | Ma et al. | Oct 2010 | A1 |
| 20110196478 | Torosoff | Aug 2011 | A1 |
| 20110301549 | Hartmann | Dec 2011 | A1 |
| 20110301594 | Orion et al. | Dec 2011 | A1 |
| 20130008780 | Andreacchi et al. | Jan 2013 | A1 |
| 20130030461 | Marks et al. | Jan 2013 | A1 |
| 20130072960 | Schneider et al. | Mar 2013 | A1 |
| 20130281788 | Garrison | Oct 2013 | A1 |
| 20130345739 | Brady et al. | Dec 2013 | A1 |
| 20140025152 | Headley | Jan 2014 | A1 |
| 20140188127 | Dubrul et al. | Jul 2014 | A1 |
| 20140276074 | Warner | Sep 2014 | A1 |
| 20140277013 | Sepetka et al. | Sep 2014 | A1 |
| 20140277079 | Vale et al. | Sep 2014 | A1 |
| 20140309673 | Dacuycuy et al. | Oct 2014 | A1 |
| 20140309675 | Maisano et al. | Oct 2014 | A1 |
| 20140343595 | Monstadt et al. | Nov 2014 | A1 |
| 20140364896 | Consigny | Dec 2014 | A1 |
| 20150133990 | Davidson | May 2015 | A1 |
| 20150297251 | Sos | Oct 2015 | A1 |
| 20150359547 | Vale et al. | Dec 2015 | A1 |
| 20160015402 | Brady et al. | Jan 2016 | A1 |
| 20160015935 | Chan et al. | Jan 2016 | A1 |
| 20160106448 | Brady et al. | Apr 2016 | A1 |
| 20160106449 | Brady | Apr 2016 | A1 |
| 20160113663 | Brady et al. | Apr 2016 | A1 |
| 20160113665 | Brady et al. | Apr 2016 | A1 |
| 20160151618 | Powers et al. | Jun 2016 | A1 |
| 20160157985 | Vo et al. | Jun 2016 | A1 |
| 20160199620 | Pokorney et al. | Jul 2016 | A1 |
| 20160228681 | Di Palma et al. | Aug 2016 | A1 |
| 20160296690 | Kume et al. | Oct 2016 | A1 |
| 20160302808 | Loganathan et al. | Oct 2016 | A1 |
| 20160331377 | Divino et al. | Nov 2016 | A1 |
| 20160375180 | Anzai | Dec 2016 | A1 |
| 20170079766 | Wang et al. | Mar 2017 | A1 |
| 20170079767 | Leon-Yip | Mar 2017 | A1 |
| 20170086862 | Vale et al. | Mar 2017 | A1 |
| 20170100143 | Grandfield | Apr 2017 | A1 |
| 20170105743 | Vale et al. | Apr 2017 | A1 |
| 20170164963 | Goyal | Jun 2017 | A1 |
| 20170215902 | Leynov et al. | Aug 2017 | A1 |
| 20170215955 | Hancock et al. | Aug 2017 | A1 |
| 20170224953 | Tran et al. | Aug 2017 | A1 |
| 20170281909 | Northrop et al. | Oct 2017 | A1 |
| 20170290599 | Youn et al. | Oct 2017 | A1 |
| 20170367707 | Divino | Dec 2017 | A1 |
| 20180049762 | Seip et al. | Feb 2018 | A1 |
| 20180084982 | Yamashita et al. | Mar 2018 | A1 |
| 20180116717 | Taff et al. | May 2018 | A1 |
| 20180132876 | Zaidat | May 2018 | A1 |
| 20180133436 | Garrison et al. | May 2018 | A1 |
| 20180140314 | Goyal et al. | May 2018 | A1 |
| 20180140315 | Bowman et al. | May 2018 | A1 |
| 20180140354 | Lam et al. | May 2018 | A1 |
| 20180161541 | Haldis et al. | Jun 2018 | A1 |
| 20180185614 | Garrison et al. | Jul 2018 | A1 |
| 20180200040 | Wasdyke et al. | Jul 2018 | A1 |
| 20180236221 | Opie et al. | Aug 2018 | A1 |
| 20180303595 | Opie et al. | Oct 2018 | A1 |
| 20180344970 | Kornowski et al. | Dec 2018 | A1 |
| 20190038438 | John | Feb 2019 | A1 |
| 20190046119 | Oxley | Feb 2019 | A1 |
| 20190175199 | Girdhar | Jun 2019 | A1 |
| 20190175200 | Girdhar et al. | Jun 2019 | A1 |
| 20190262069 | Taff et al. | Aug 2019 | A1 |
| 20190336727 | Yang et al. | Nov 2019 | A1 |
| 20190388097 | Girdhar et al. | Dec 2019 | A1 |
| 20190388107 | Girdhar et al. | Dec 2019 | A1 |
| 20190388111 | Nguyen et al. | Dec 2019 | A1 |
| 20190388112 | Nguyen | Dec 2019 | A1 |
| 20200129742 | Cope et al. | Apr 2020 | A1 |
| 20200297367 | Girdhar et al. | Sep 2020 | A1 |
| 20200297410 | Nguyen et al. | Sep 2020 | A1 |
| 20200390455 | Nguyen et al. | Dec 2020 | A1 |
| 20200390456 | Nguyen et al. | Dec 2020 | A1 |
| 20200390457 | Nageswaran et al. | Dec 2020 | A1 |
| 20200390458 | Nguyen et al. | Dec 2020 | A1 |
| 20210068853 | Nguyen et al. | Mar 2021 | A1 |
| 20210238764 | Tyvoll et al. | Aug 2021 | A1 |
| 20220202431 | Davidson et al. | Jun 2022 | A1 |
| 20220236569 | Yamazaki et al. | Jul 2022 | A1 |
| Number | Date | Country |
|---|---|---|
| 101472685 | Jul 2009 | CN |
| 104884681 | May 2018 | CN |
| 2319575 | Nov 2013 | EP |
| 2490764 | Sep 2014 | EP |
| 2895645 | Jul 2015 | EP |
| 3184067 | Jun 2017 | EP |
| 10290805 | Nov 1998 | JP |
| 2014004219 | Jan 2014 | JP |
| 2018118132 | Aug 2018 | JP |
| 20180102877 | Sep 2018 | KR |
| 2009127037 | Oct 2009 | WO |
| 2010061376 | Jun 2010 | WO |
| 2014079148 | May 2014 | WO |
| 2015141317 | Sep 2015 | WO |
| 2016198947 | Dec 2016 | WO |
| 2017192999 | Nov 2017 | WO |
| 2018019829 | Feb 2018 | WO |
| 2018033401 | Feb 2018 | WO |
| 2018046408 | Mar 2018 | WO |
| 2018127796 | Jul 2018 | WO |
| 2018137029 | Aug 2018 | WO |
| 2018137030 | Aug 2018 | WO |
| 2018145212 | Aug 2018 | WO |
| 2018156813 | Aug 2018 | WO |
| 2018172891 | Sep 2018 | WO |
| 2018187776 | Oct 2018 | WO |
| 2019102307 | May 2019 | WO |
| 2019118321 | Jun 2019 | WO |
| 2019246377 | Dec 2019 | WO |
| Entry |
|---|
| International Search Report and Written Opinion dated May 25, 2020, International Application No. PCT/US20/22463, 10 pages. |
| International Search Report and Written Opinion dated Nov. 3, 2020, International Application No. PCT/US20/70142, 18 pages. |
| Fort, Stephen , et al., “‘Fused-Gold’ vs. ‘Bare’ stainless steel NIRflex stents of the same geometric design in diseased native coronary arteries. Long-term results from the NIR TOP Study”, Euro Interv 2007; 3:256-261. |
| International Search Report and Written Opinion dated Mar. 24, 2022; International Application No. PCT/US2021/061540; 10 pages. |
| Number | Date | Country | |
|---|---|---|---|
| 20220287765 A1 | Sep 2022 | US |
